TNFRSF17 and Miyoshi myopathy: Furthermore, anti‐BCMA CAR‐T immunotherapy has provided good response rates in pretreated/refractory MM patients, however, the median progression free survival remains relatively short, ranging from 11 to 15 months depending on the study [7, 8].